Revisiting REVISIT: The Case for Ceftazidime/Avibactam Plus Aztreonam
We commend Carmeli and colleagues on their publication summarizing the findings of the REVISIT trial 1 .The trial evaluated 422 patients with pneumonia or intra-abdominal infections caused by gram-negative bacteria, randomized to receive aztreonam/avibactam (ATM/AVI metronidazole) or meropenem ( colistin).The study found similar rates of clinical cure and survival between the groups.The authors concluded that ATM/AVI represents a promising therapeutic option for gram-negative infections while appropriately cautioning that the limited number of patients with metallo-beta-lactamase (MBL)-producing infections -only three patients
Authors
- Robert A. Bonomo (ORCID: https://orcid.org/0000-0002-3299-894X)
- Federico Perez (ORCID: https://orcid.org/0000-0003-2642-3266)
- Pranita D. Tamma (ORCID: https://orcid.org/0000-0002-4143-6324)
- Thomas P. Lodise (ORCID: https://orcid.org/0000-0002-4730-0655)
- María F. Mojica (ORCID: https://orcid.org/0000-0002-1380-9824)
Institutions
- Johns Hopkins University (US)
- Johns Hopkins Medicine (US)
- Albany College of Pharmacy and Health Sciences (US)
- Louis Stokes Cleveland VA Medical Center (US)
- University School (US)
- Case Western Reserve University (US)
Publication Details
- Journal
- Clinical Infectious Diseases
- Published
- 2025-05-09
- DOI
- https://doi.org/10.1093/cid/ciaf239
- Citations
- 3
- Primary Topic
- Hemoglobinopathies and Related Disorders
- Type
- article
- Field-Weighted Citation Impact
- 4.88